Morton Coleman, MD Distinguished Professor of Medicine NewYork Presbyterian Hospital, Weill Cornell Medicine New York, New York
Learning Objectives:
Assess the current treatment options for CLL beyond the current chemoimmunotherapy (CIT) standard
Incorporate patient preferences and AE management strategies into patient centered treatment decisions.
Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with major emerging agents, including Anti CD-20 mABs, BCL-2 inhibitors, and BTK inhibitors
Incorporate patient preferences and AE management strategies into patient centered treatment decisions.